BioCentury | Jun 27, 2017
Distillery Techniques

Disease models

...combination of a mAb against bacterial ClfA and a mAb targeting a S. aureus toxin (MEDI4893...
...LLC unit of AstraZeneca plc include developing undisclosed therapies screened in the model. MedImmune has MEDI4893...
BioCentury | Feb 23, 2015
Clinical News

MEDI4893: Phase II started

...double-blind, placebo-controlled, dose-ranging European Phase II SAATELLITE trial to evaluate 2 single doses of IV MEDI4893...
...challenges of rising antimicrobial resistance in Europe. AstraZeneca pl c (LSE:AZN; NYSE:AZN), London, U.K. Product: MEDI4893...
BioCentury | Feb 12, 2015
Targets & Mechanisms

High five for Arsanis

...associate director of the Koch Institute for Integrative Cancer Research at MIT. AstraZeneca plc has MEDI4893...
BioCentury | Dec 19, 2012
Politics & Policy

IMI expanding ND4BB

...now seeking to fund projects focused on innovative trial design and clinical drug development of MEDI4893...
...by the MedImmune LLC unit of AstraZeneca plc (LSE:AZN; NYSE:AZN). A Phase Ib/IIa trial of MEDI4893...
BioCentury | Jun 4, 2012
Strategy

Innovating antibiotics

...molecules from AstraZeneca may join GSK1322322 in the clinic, pending the results from ongoing studies. MEDI4893...
BioCentury | May 28, 2012
Company News

AstraZeneca, GlaxoSmithKline infectious news

...MEDI4893, a mAb targeting a Staphylococcus aureus toxin. AZD9773 is in Phase II testing, while MEDI4893...
BioCentury | May 25, 2012
Company News

IMI launches antibiotic research program

...also plans to support the development at a later date of two products from AstraZeneca: MEDI4893...
...fragment against tumor necrosis factor (TNF) alpha . AZD9773 is in Phase II testing, while MEDI4893...
Items per page:
1 - 7 of 7